Literature DB >> 3190987

Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach.

J H Schellens1, J H van der Wart, M Danhof, E A van der Velde, D D Breimer.   

Abstract

1. Three model substrates for the characterization of drug oxidation activity, antipyrine (AP), hexobarbitone (HB) and theophylline (TH), were administered to 26 healthy volunteers on two different occasions: in the first experiment a combination of AP (250 mg) and HB (250 mg) was given and in the second experiment TH (150 mg) was added to the former combination. 2. Plasma concentrations of AP, HB and TH and urinary excretion of TH and the three main metabolites of AP (3-hydroxymethylantipyrine: HMA, norantipyrine: NORA and 4-hydroxyantipyrine: OHA) were determined and the intrinsic clearance (CLint) of the three substrates and the clearance to the formation of AP metabolites were calculated. 3. The correlation coefficients between CLHB and CL-greater than metabolites of AP were highest for CL-greater than HMA and CL-greater than NORA (greater than 0.80) and lowest for CL-greater than OHA (0.63). High correlation coefficients also were found between CLTH and CL-greater than OHA (0.89) and CL-greater than HMA (0.80). 4. Ideal relationships, defined by a slope of the orthogonal regression line equal to unity, did exist between CLHB and CL-greater than HMA as well as CL-greater than NORA and between CLTH and CLAP as well as CL-greater than OHA. 5. Based on the results of correlation and regression analysis it can be concluded that isozymes of the cytochrome P-450 system responsible for the oxidation of HB and formation of HMA and NORA are very closely related and also that isozymes responsible for the oxidation of TH and formation of OHA show a very close relation. 6. With this strategy of simultaneous administration of substrates ('cocktail' approach) it seems possible to characterize and correlate activities of different P-450 isozymes and to investigate their in vivo substrate selectivity without the disturbing influence of intra-individual variation in drug oxidation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190987      PMCID: PMC1386557          DOI: 10.1111/j.1365-2125.1988.tb03394.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

Review 1.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

2.  New directions in pharmacogenetics: Introduction.

Authors:  E S Vesell
Journal:  Fed Proc       Date:  1984-05-15

3.  Interindividual variations in drug disposition. Clinical implications and methods of investigation.

Authors:  D D Breimer
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

4.  Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4'-dihydroxyantipyrine.

Authors:  M W Teunissen; J E Meerburg-van der Torren; N P Vermeulen; D D Breimer
Journal:  J Chromatogr       Date:  1983-12-09

5.  Variability in caffeine metabolism.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-05       Impact factor: 6.875

6.  Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats.

Authors:  M van der Graaff; N P Vermeulen; R P Joeres; T Vlietstra; D D Breimer
Journal:  J Pharmacol Exp Ther       Date:  1983-11       Impact factor: 4.030

7.  Pharmacokinetics of simultaneously administered hexobarbital and heptabarbital in rats: an alternative approach to metabolic correlation studies.

Authors:  M van der Graaff; N P Vermeulen; P N Langendijk; D D Breimer
Journal:  J Pharmacol Exp Ther       Date:  1983-06       Impact factor: 4.030

8.  Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction.

Authors:  D J Birkett; J O Miners; J Attwood
Journal:  Br J Clin Pharmacol       Date:  1983-05       Impact factor: 4.335

9.  Differential induction of antipyrine metabolism by rifampicin.

Authors:  E L Toverud; A R Boobis; M J Brodie; S Murray; P N Bennett; V Whitmarsh; D S Davies
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

10.  Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.

Authors:  A R Boobis; M J Brodie; G C Kahn; E L Toverud; I A Blair; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

View more
  17 in total

1.  Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers.

Authors:  Adriana Rocha; Eduardo B Coelho; Stefânia A Sampaio; Vera L Lanchote
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics 1990.

Authors:  G R Matzke; W L St Peter
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 4.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  M T Kinirons; P Crome
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

5.  Effect of short-term omeprazole administration on serum pepsinogens in relation to fasting serum gastrin and gastric acid secretion.

Authors:  I Biemond; L F Crobach; J B Jansen; C B Lamers
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

6.  Influence of subject age on the inhibition of oxidative metabolism by ciprofloxacin.

Authors:  N M Waite; M J Rybak; D J Krakovsky; J D Steinberg; L H Warbasse; D J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

7.  Lack of pharmacokinetic interaction between nifedipine, sparteine and phenytoin in man.

Authors:  J H Schellens; P A Soons; J H van der Wart; J W Hoevers; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

8.  The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women.

Authors:  K Groen; M A Horan; N A Roberts; R S Gulati; B Miljkovic; E J Jansen; V Paramsothy; D D Breimer; C F van Bezooijen
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

9.  Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers.

Authors:  Adriana Rocha; Eduardo B Coelho; Soraia A P Moussa; Vera L Lanchote
Journal:  Eur J Clin Pharmacol       Date:  2008-06-26       Impact factor: 2.953

10.  Two- and four-day rifampin chemoprophylaxis regimens induce oxidative metabolism.

Authors:  S M Borcherding; T L Bastian; T H Self; N Abou-Shala; B W LeDuc; R L Lalonde
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.